BioStem Registers 12.05M Shares for $40M Roth Equity Facility — Potential 40% Dilution
BSEM has more than doubled off its 52-week low of $2.251 on elevated volume (8.8× avg).
Summary
BioStem filed an S-1 to register 12.05M shares for resale under its new $40M committed equity facility with Roth Principal Investments. If fully issued, the shares would represent ~40% dilution to existing holders.
Key Events · Financing and Capital Events · BSEM
-
$40M Committed Equity Facility Registered
S-1 registers 12,050,000 shares for resale by Roth Principal Investments under the Purchase Agreement dated September 18, 2026. The company may sell up to $40M of common stock over 36 months at its discretion.
-
Potential 40% Dilution
If all 12,050,000 registered shares are issued, they would represent approximately 40.2% of the 17,935,843 shares outstanding as of September 17, 2026, and 46.5% of non-affiliate shares.
-
Pricing Mechanics
Purchase price is 97% of VWAP for market open/intraday purchases and 95% for pre/post-market purchases, subject to a $1.00 threshold price. The company controls timing and amount of sales.
-
Exchange Cap and Ownership Limits
Issuance capped at 3,585,375 shares (19.99% of outstanding) without stockholder approval, unless average price paid equals or exceeds $4.3056. Roth's beneficial ownership limited to 4.99%.
Analysis · BSEM · Life Sciences
This S-1 registers 12,050,000 shares for resale under the $40M committed equity facility announced earlier today. The filing quantifies the dilution: if all registered shares are issued, they would represent approximately 40.2% of the 17.9M shares outstanding. The purchase price is set at 97% of VWAP for intraday purchases and 95% for pre/post-market, with a $1.00 floor. The company controls timing and amount of sales, but the overhang is substantial for a company with a going-concern warning and only $6.96M in cash as of June 30, 2026. The Exchange Cap limits issuance to 3,585,375 shares (19.99%) without stockholder approval, but the registration covers the full 12.05M shares, signaling intent to potentially access the full facility.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.2% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $4.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $2.25 to $8.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.